Hurdle cleared:
"Additional experiments will now be performed on SARS-CoV-2 infected human lung cell lines."
Now the sell through? This is extremely promising news - the company is looking more and more likely to be sitting on a very safe and very effective anti-viral to treat CoV infections, including COVID-19, just at a time that the world is waking up the reality that vaccines alone won't be enough. This ought to be shouted from the rooftops, so let's see how management does with its (apparently) refreshed approach to comms...
Ann: Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity, page-10
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
-0.025(10.2%) |
Mkt cap ! $86.90M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 24.5¢ | 22.0¢ | $405.6K | 1.791M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 32271 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 53448 | 2 |
View Market Depth
| Last trade - 16.10pm 30/04/2024 (20 minute delay) ? |
|
|||||
|
Last
22.5¢ |
Change
-0.025 ( 8.16 %) |
||||
| Open | High | Low | Volume | ||
| 24.0¢ | 24.0¢ | 22.0¢ | 900359 | ||
| Last updated 15.56pm 30/04/2024 ? | |||||
| PAA (ASX) Chart |